Advancements in Targeted Therapies Improve Survival in Breast Cancer
• Recent trials highlight the benefits of CDK4/6 inhibitors like abemaciclib and ribociclib in high-risk, HR+/HER2- early breast cancer, improving invasive disease-free survival.
• Checkpoint inhibitors such as pembrolizumab and nivolumab show promise in treating high-risk, HR+/HER2- breast cancer, particularly in patients with high PDL1 expression and low estrogen receptor expression.
• Trastuzumab deruxtecan has demonstrated improved progression-free survival in HER2-low, HR+/HER2- metastatic breast cancer, marking a significant advancement in treatment options.
• The RxPONDER trial indicates that adjuvant chemotherapy may not benefit all premenopausal patients, with AMH levels predicting which patients will benefit from chemotherapy.
© Copyright 2025. All Rights Reserved by MedPath